Market Cap 679.49M
Revenue (ttm) 891.97M
Net Income (ttm) -117.12M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -13.13%
Debt to Equity Ratio 0.00
Volume 79,000
Avg Vol 47,412
Day's Range N/A - N/A
Shares Out 355.76M
Stochastic %K 43%
Beta 1.92
Analysts Sell
Price Target $2.80

Company Profile

Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just – Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, immunology, pain and inflammation, infectious, kidney, liver, respiratory, fibrotic and metabolic diseases, and rare diseases. It is...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 49 40 560 81 0
Address:
Essener Bogen 7, Hamburg, Germany
SharpEntry_
SharpEntry_ Jul. 16 at 12:58 PM
$EVO This is exactly why patience matters in trading. A lot of people want to jump in the moment a setup appears, but confirmation is everything. If you bought right when the previous post came out, you’d already be sitting on a ~30% loss within days. The chart is still showing weakness, and price action continues to suggest there may be more downside ahead. Good trades are not about catching every move. They’re about waiting for the right moment, protecting capital, and letting the chart prove the setup before taking a position.
0 · Reply
Merlintrader
Merlintrader Jul. 14 at 12:02 PM
$BIIB Biotech Radar July 14, 2026: Biogen, AstraZeneca, GSK and Evotec — $BIIB, $AZN, $GSK, $EVO https://www.merlintrader.com/biotech-radar-july14-2026/
0 · Reply
BillionerOfKing
BillionerOfKing Jul. 8 at 6:00 PM
$EVO Current Stock Price: $2.76
0 · Reply
AlexeiMoro
AlexeiMoro Jun. 17 at 8:56 PM
$EVO around 11–12x earnings, which is unusually low for a company that still generates extremely high margins and strong cash flow..,
0 · Reply
coolmate25
coolmate25 Jun. 10 at 5:59 PM
$EVO Wall Street analysts place the consensus 12-month price target for Evotec SE (NASDAQ: EVO) at roughly $5.20 per share, indicating a potential upside of approximately +69% compared to current trading levels. Forecasts range widely, with a high estimate of $7.00 .
0 · Reply
SuperGreenToday
SuperGreenToday Jun. 9 at 8:57 PM
0 · Reply
coolmate25
coolmate25 Jun. 8 at 4:43 PM
$EVO Such a nice stock , why is it not moving?
0 · Reply
peloswing
peloswing May. 13 at 1:27 PM
$EVO -12% in pre-market following €116.1 Million Convertible Bond headline 🔻
0 · Reply
KOWALSK1
KOWALSK1 Apr. 20 at 6:56 PM
0 · Reply
AnonMav
AnonMav Apr. 17 at 3:11 PM
$EVO Reclaim story begins
0 · Reply
Latest News on EVO
Evotec SE Earnings Call Transcript: Q2 2026

Jul 14, 2026, 8:00 AM EDT - 20 days ago

Evotec SE Earnings Call Transcript: Q2 2026


Evotec SE Earnings release: Q2 2026

Jul 14, 2026, 8:00 AM EDT - 20 days ago

Evotec SE Earnings release: Q2 2026


Evotec SE Slides: Q2 2026

Jul 14, 2026, 8:00 AM EDT - 20 days ago

Evotec SE Slides: Q2 2026


Evotec SE Proxy statement: Proxy filing

Jun 23, 2026, 8:00 AM EDT - 5 weeks ago

Evotec SE Proxy statement: Proxy filing


Evotec SE Slides: Company presentation

Jun 17, 2026, 1:00 AM EDT - 6 weeks ago

Evotec SE Slides: Company presentation


Evotec Reports Results of the Annual General Meeting 2026

Jun 11, 2026, 12:02 PM EDT - 7 weeks ago

Evotec Reports Results of the Annual General Meeting 2026

EVO


Evotec Appoints Rui Wang as Head of Global In Silico and AI

Jun 2, 2026, 1:45 AM EDT - 2 months ago

Evotec Appoints Rui Wang as Head of Global In Silico and AI

EVO


Evotec Receives Grants to Advance Tuberculosis Treatment

Apr 30, 2026, 3:20 AM EDT - 3 months ago

Evotec Receives Grants to Advance Tuberculosis Treatment

EVO


Evotec Announces New Nomination to Board of Directors

Apr 29, 2026, 4:45 PM EDT - 3 months ago

Evotec Announces New Nomination to Board of Directors

EVO


Evotec SE to Announce First Quarter 2026 Results on May 6, 2026

Apr 29, 2026, 1:50 AM EDT - 3 months ago

Evotec SE to Announce First Quarter 2026 Results on May 6, 2026

EVO


Evotec Announces Chief Financial Officer Transition

Apr 24, 2026, 1:50 AM EDT - 3 months ago

Evotec Announces Chief Financial Officer Transition

EVO


Evotec Appoints Dr. Ingrid Müller as Chief Operating Officer

Apr 15, 2026, 1:50 AM EDT - 3 months ago

Evotec Appoints Dr. Ingrid Müller as Chief Operating Officer

EVO


Evotec SE Earnings Call Transcript: Q4 2025

Apr 8, 2026, 8:00 AM EDT - 4 months ago

Evotec SE Earnings Call Transcript: Q4 2025


Evotec Nominates Dieter Weinand as Supervisory Board Chairman

Apr 7, 2026, 3:00 AM EDT - 4 months ago

Evotec Nominates Dieter Weinand as Supervisory Board Chairman

EVO


Evotec Appoints Dr. Ashiq H. Khan as Chief Commercial Officer

Apr 1, 2026, 1:50 AM EDT - 4 months ago

Evotec Appoints Dr. Ashiq H. Khan as Chief Commercial Officer

EVO


Evotec SE Earnings Call Transcript: Q1 2025

May 6, 2025, 8:00 AM EDT - 1 year ago

Evotec SE Earnings Call Transcript: Q1 2025


Evotec Announces Change in Management Board

Feb 26, 2025, 2:00 AM EST - 1 year ago

Evotec Announces Change in Management Board

EVO


Comment on Withdrawn Non-Binding Offer

Nov 22, 2024, 11:15 AM EST - 1 year ago

Comment on Withdrawn Non-Binding Offer

EVO


Halozyme withdraws $2.1 bln buyout offer for Evotec

Nov 22, 2024, 8:55 AM EST - 1 year ago

Halozyme withdraws $2.1 bln buyout offer for Evotec

EVO HALO


SharpEntry_
SharpEntry_ Jul. 16 at 12:58 PM
$EVO This is exactly why patience matters in trading. A lot of people want to jump in the moment a setup appears, but confirmation is everything. If you bought right when the previous post came out, you’d already be sitting on a ~30% loss within days. The chart is still showing weakness, and price action continues to suggest there may be more downside ahead. Good trades are not about catching every move. They’re about waiting for the right moment, protecting capital, and letting the chart prove the setup before taking a position.
0 · Reply
Merlintrader
Merlintrader Jul. 14 at 12:02 PM
$BIIB Biotech Radar July 14, 2026: Biogen, AstraZeneca, GSK and Evotec — $BIIB, $AZN, $GSK, $EVO https://www.merlintrader.com/biotech-radar-july14-2026/
0 · Reply
BillionerOfKing
BillionerOfKing Jul. 8 at 6:00 PM
$EVO Current Stock Price: $2.76
0 · Reply
AlexeiMoro
AlexeiMoro Jun. 17 at 8:56 PM
$EVO around 11–12x earnings, which is unusually low for a company that still generates extremely high margins and strong cash flow..,
0 · Reply
coolmate25
coolmate25 Jun. 10 at 5:59 PM
$EVO Wall Street analysts place the consensus 12-month price target for Evotec SE (NASDAQ: EVO) at roughly $5.20 per share, indicating a potential upside of approximately +69% compared to current trading levels. Forecasts range widely, with a high estimate of $7.00 .
0 · Reply
SuperGreenToday
SuperGreenToday Jun. 9 at 8:57 PM
0 · Reply
coolmate25
coolmate25 Jun. 8 at 4:43 PM
$EVO Such a nice stock , why is it not moving?
0 · Reply
peloswing
peloswing May. 13 at 1:27 PM
$EVO -12% in pre-market following €116.1 Million Convertible Bond headline 🔻
0 · Reply
KOWALSK1
KOWALSK1 Apr. 20 at 6:56 PM
0 · Reply
AnonMav
AnonMav Apr. 17 at 3:11 PM
$EVO Reclaim story begins
0 · Reply
KOWALSK1
KOWALSK1 Apr. 16 at 10:50 PM
0 · Reply
BioTuesdays
BioTuesdays Apr. 15 at 2:53 PM
$EVO has appointed Dr. Ingrid Müller as Chief Operating Officer (COO), effective May 1, 2026. https://biotuesdays.com/2026/04/15/dr-ingrid-muller-joins-evotec-as-coo/
0 · Reply
LewisDaKat
LewisDaKat Apr. 15 at 10:31 AM
$EVO Evotec Appoints Dr. Ingrid M ller as Chief Operating Officer https://marketwirenews.com/stock/evo/news/evotec-appoints-dr-ingrid-m-xfc-ller-as-chief-operat-6497978197933043.html?utm_source=stocktwits
0 · Reply
AnonMav
AnonMav Apr. 14 at 9:56 AM
$EVO 1st sign of life 👍
0 · Reply
AnonMav
AnonMav Apr. 12 at 1:47 AM
$EVO Six levels painted. You're at the bottom of the structure, grinding on purple. Below $2.52 = pain. Above $2.95 = first sign of life. Everything above $3.28 is a reclaim story. Don't hold your breath but keep it on the radar. 🤙 https://share.trendspider.com/chart/EVO/94993v3s3vk?_go=anonmav
0 · Reply
investmentstarry
investmentstarry Apr. 2 at 8:45 AM
$EVO — Capital Allocation Update 💡 Board proposes ZERO dividend for 2025 Company pivoting toward share buybacks I like this move — better capital allocation while valuation remains low (PE ~10x)
0 · Reply
BioTuesdays
BioTuesdays Apr. 1 at 2:55 PM
$EVO has appointed Dr. Ashiq H. Khan as EVP global head, chief commercial officer (CCO). https://biotuesdays.com/2026/04/01/evotec-appoints-dr-ashiq-h-khan-as-cco/
0 · Reply
KOWALSK1
KOWALSK1 Mar. 24 at 11:54 AM
$EVO Evotec ag ✅️ BUY ZONE 2.39 to 2.38 ✋️ RISK BELOW 2.21 🎯 PT. 2.50 2.59 2.70 2.97 3.12 + UP Follow for more
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 16 at 6:41 PM
$EVO Current Stock Price: $3.52
0 · Reply
ShadowGale
ShadowGale Feb. 4 at 2:08 PM
$EVO is a payment technology and services company; it operates in a consolidating industry and must invest to keep pace with technological change.
0 · Reply